Liver cancer biomarkers

• US 20050152908A1
• Filed: 11/03/2004
• Published: 07/14/2005
• Est. Priority Date: 11/03/2003
• Status: Abandoned Application

• Current Assignee: GeneNews Inc. (StageZero Life Sciences Ltd.)
• Original Assignee: GeneNews Inc. (StageZero Life Sciences Ltd.)
• Inventors: Dempsey, Adam, Liew, Choong-Chin, Chao, Samuel, Yager, Thomas
• Application Number:
  US10/980,850
• Publication Number:
  US 20050152908A1
• Time in Patent Office: Days
• US Class Current: 424/155.100
• CPC Class Codes: C07K 14/00 Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• CPC Class Codes: C07K 16/303 Liver or Pancreas

Abstract

The invention relates to the identification and selection of biomarkers which demonstrate particular advantage in identifying individuals having liver cancer. The invention further relates to useful combinations of biomarkers for diagnosing liver cancer. The invention further provides for the polynucleotides and polypeptides and kits thereof for use as a tool to diagnose disease and to monitor the efficacy of therapeutic regimens. The invention further provides a method of selecting biomarker combinations and the combinations thus identified for diagnosis of liver cancer. Also encompassed by the invention are screening methods to identify therapeutic targets for treating liver cancer, and identify single nucleotide point mutations related to liver cancer.

Claims

1. A composition comprising a collection of two or more isolated polynucleotides, said polynucleotides which selectively hybridize to at least two biomarkersof the invention, wherein the biomarkers are selected from the group consisting of the genes:

amyloid beta (A4) precursor-like protein 2 (APLP2);

BCL2-related protein A1 (BCL2A1);

phosphoprotein regulated by mitogenic pathways (C8FW);

CD14 antigen (CD14);

Complement Component 5 (C5);

C-type lectin-like receptor-2 (CLEC2);

CDC-like kinase 1 (CLK1);

Clusterin (CLU);

cathepsin B (CTSB);

cortactin (CTTN);

ficolin (collagen/fibrinogen domain containing) 1 (FCN1);

Putative lymphocyte G0/G1 switch gene (G0S2);

interleukin 23A (IL23A);

IGF-II mRNA-binding protein 3 (IMP-3);

killer cell lectin-like receptor subfamily B, member 1 (KLRB1);

2′

,5′

-oligoadenylate synthetase 1 (OAS1);

2′

-5′

-oligoadenylate synthetase 3 (OAS3) RAR-related orphan receptor A (RORA);

Related RAS viral (r-ras) oncogene homolog 2 (RRAS2) synuclein, alpha (non A4 component of amyloid precursor (SNCalif.);

Homo sapiens serinethreonine kinase 17b (apoptosis-inducing) (STK17B);

transcription factor EC (TFEC);

killer cell lectin-like receptor subfamily B, and as set out in Table 1 and wherein the composition is used to measure the level of expression of said biomarker.

15. The composition of any one of claims 1, 2, 4, 6, 7 or 8, wherein the isolated olynucleotides are single or double stranded RNA.

16. The composition of any one of claims 1, 2, 4, 6, 7 or 8, wherein the isolated polynucleotides are single or double stranded DNA.

2. A composition comprising a collection of two or more isolated polynucleotides which bind selectively to the RNA products of at least two biomarkers, wherein the biomarkers are selected from the group consisting of the genes:

amyloid beta (A4) precursor-like protein 2 (APLP2);

BCL2-related protein A1 (BCL2A1);

phosphoprotein regulated by mitogenic pathways (C8FW);

CD14 antigen (CD14);

Complement Component 5 (C5);

C-type lectin-like receptor-2 (CLEC2);

CDC-like kinase 1 (CLK1);

Clusterin (CLU);

cathepsin B (CTSB);

cortactin (CTTN);

ficolin (collagen/fibrinogen domain containing) 1 (FCN1);

Putative lymphocyte G0/G1 switch gene (G0S2);

interleukin 23A (IL23A);

IGF-II mRNA-binding protein 3 (IMP-3);

killer cell lectin-like receptor subfamily B, member 1 (KLRB1)2′

,5′

-oligoadenylate synthetase 1 (OAS

     1);

2′

-5′

-oligoadenylate synthetase 3 (OAS3) RAR-related orphan receptor A (RORA);

Related RAS viral (r-ras) oncogene homolog 2 (RRAS2) synuclein, alpha (non A4 component of amyloid precursor (SNCA);

Homo sapiens serinethreonine kinase 17b (apoptosis-inducing) (STK17B);

transcription factor EC (TFEC)as set out in Table 1.

3. The composition of claim 2 wherein said polynucleotides are useful in quantitative RT-PCR (QRT-PCR).

4. A composition comprising a collection of two or more isolated proteins which bind selectively to the protein products of at least two biomarkers, wherein the biomarkers are selected from the group consisting of the genes:

amyloid beta (A4) precursor-like protein 2 (APLP2);

BCL2-related protein A1 (BCL2A1);

phosphoprotein regulated by mitogenic pathways (C8FW);

CD14 antigen (CD14);

Complement Component 5 (C5);

C-type lectin-like receptor-2 (CLEC2);

CDC-like kinase 1 (CLK1);

Clusterin (CLU);

cathepsin B (CTSB);

cortactin (CTTN);

ficolin (collagen/fibrinogen domain containing) 1 (FCN1);

Putative lymphocyte G0/G1 switch gene (G0S2);

interleukin 23A (IL23A);

IGF-II mRNA-binding protein 3 (IMP-3);

killer cell lectin-like receptor subfamily B, member 1 (KLRB1);

2′

,5′

-oligoadenylate synthetase 1 (OAS1);

2′

-5′

-oligoadenylate synthetase 3 (OAS3) RAR-related orphan receptor A (RORA);

Related RAS viral (r-ras) oncogene homolog 2 (RRAS2);

synuclein, alpha (non A4 component of amyloid precursor (SNCA);

Homo sapiens serinethreonine kinase 17b (apoptosis-inducing) (STKl 7B);

transcription factor EC (TFEC) as set out in Table 1

5. A composition comprising a collection of two or more isolated polynucleotides which bind selectively to at least two biomarkers, wherein the biomarkers are selected from the group consisting of the genes:

BCL2-related protein A1 (BCL2A1);

phosphoprotein regulated by mitogenic pathways (C8FW);

CD14 antigen (CD

     14);

C-type lectin-like receptor-2 (CLEC2);

CDC-like kinase 1 (CLK1);

Clusterin (CLU);

Putative lymphocyte G0/G1 switch gene (G0S2);

interleukin 23A (L23A);

killer cell lectin-like receptor subfamily B, member 1 (KLRB1) or synuclein, alpha (non A4 component of amyloid precursor (SNCA);

listed in Table 2.

6. A composition comprising a collection of isolated proteins, which bind selectively to the protein products of biomarkers, wherein the biomarkers are selected from the group consisting of the genes:

BCL2-related protein A1 (BCL2A1);

phosphoprotein regulated by mitogenic pathways (C8FW);

CD14 antigen (CD14);

C-type lectin-like receptor-2 (CLEC2);

CDC-like kinase 1 (CLK1);

Clusterin (CLU);

Putative lymphocyte G0/G1 switch gene (G0S2);

interleukin 23A (IL23A);

killer cell lectin-like receptor subfamily B, member 1 (KLRB1) or synuclein, alpha (non A4 component of amyloid precursor (SNCA);

as set out in Table 2

7. A composition comprising a collection of isolated polynucleotides which bind selectively to the RNA products of biomarkers, wherein the biomarkers are selected from the group of genes:

BCL2-related protein A1 (BCL2A1);

phosphoprotein regulated by mitogenic pathways (C8FW);

CD14 antigen (CD14);

C-type lectin-like receptor-2 (CLEC2);

CDC-like kinase 1 (CLK1);

Clusterin (CLU);

Putative lymphocyte G0/G1 switch gene (G0S2);

interleukin 23A (IL23A);

killer cell lectin-like receptor subfamily B, member 1 (KLRB1) or synuclein, alpha (non A4 component of amyloid precursor (SNCA);

as set out in Table 2.

8. A composition comprising a collection of two or more isolated polynucleotides which bind selectively to the RNA products of at least two biomarkers, wherein the RNA products are selected from the group consisting of the RNA transcripts as set out in TAble 3.

9. A composition comprising a collection of two or more isolated polynucleotides which bind selectively to the RNA products of at least two biomarkers, wherein the RNA products are selected from the group consisting of the RNA transcripts as set out in TAble 4.

10. A composition comprising a collection of two or more isolated proteins which bind selectively to the protein products of at least two biomarkers, wherein the protein products are selected from the group consisting of the RNA transcripts as set out inTable 3.

12. The composition of any one of claims 3, 5, 9 or 10, wherein the isolated proteins are ligands.

13. The composition of any one of claims 3, 5, 9 or 10, wherein the ligands are antibodies.

14. The composition of claim 12, wherein the antibodies are monoclonal antibodies.

11. A composition comprising a collection of two or more isolated proteins which bind selectively to the protein products of at least two biomarkers, wherein the protein products are selected from the group consisting of the RNA transcripts as set out in Table 4.

17. A method of diagnosing or prognosing liver cancer in an individual, comprising the steps of:

a) determining the level of one or more RNA transcriptsexpressed in blood obtained from said individual, wherein said one or more RNA transcripts corresponds to said one or more biomarkers of Table 1, and

b) comparing the level of each of said one or more RNA transcripts in said blood according to step a) with the level of each of said one or more RNA transcripts in blood from one or more individuals not having liver cancer,

wherein detecting differential expression of each of said one or more RNA transcripts in the comparison of step b) is indicative of liver cancer in the individual of step a).

22. The method of any one of claims 17-21, wherein said blood sample consists of whole blood.

23. The method of any one of claims 17-21, wherein said blood sample consists of a drop of blood.

24. The method of any one of claims 17-21, wherein said blood sample consists of blood that has been lysed.

25. The method of any one of claims 17-21, further comprising the step of isolating RNA from said blood samples.

26. The method of any one of claims 17-21, wherein the step of determining the level of each of said one or more RNA transcripts comprises quantitative RT-PCR (QRT-PCR), wherein said one or more transcripts are from step a) and/or step b) of claims 17-21.

27. The method of claim 26, wherein said QRT-PCR utilizes primers which hybridize to said one or more transcripts or the complement thereof, wherein said one or more transcripts are from step a) and/or step b) of claims 17-21.

28. The method of claim 27, wherein said primers are 15-25 nucleotides in length.

29. The method of any one of claims 17-21, wherein the step of determining the level of each of said one or more RNA transcripts comprises hybridizing a first plurality of isolated nucleic acid molecules that correspond to said one or more transcripts, to an array comprising a second plurality of isolated nucleic acid molecules.

30. The method of claim 29, wherein said first plurality of isolated nucleic acid molecules comprises RNA, DNA, cDNA, PCR products or ESTs.

31. The method of claim 29, wherein said array comprises a plurality of isolated nucleic acid molecules comprising RNA, DNA, cDNA, PCR products or ESTs.

32. The method of claim 29, wherein said second plurality of isolated nucleic acid molecules on said array comprises polynucleotides corresponding to one or more of the biomarkers of Table 1.

33. The method of claim 29, wherein said second plurality of isolated nucleic acid molecules on said array comprises polynucleotides corresponding to one or more of the biomarkers of Table 2.

34. The method of claim 29, wherein said second plurality of isolated nucleic acid molecules on said array comprises polynucleotides corresponding to one or more of the RNA products of Table 3.

35. The method of claim 29, wherein said second plurality of isolated nucleic acid molecules on said array comprises polynucleotides corresponding to one or more of the RNA products of Table 4.

18. A method of diagnosing or prognosing liver cancer in an individual, comprising the steps of:

a) determining the level of one or more RNA transcripts expressed in blood obtained from said individual, wherein said one or more RNA transcripts corresponds to said one or more biomarkers of Table 2, and

b) comparing the level of each of said one or more RNA transcripts in said blood according to step a) with the level of each of said one or more RNA transcripts in blood from one or more individuals having liver cancer,

wherein detecting the same levels of each of said one or more RNA transcripts in the comparison of step b) is indicative of cancer in the individual of step a).

19. A method of diagnosing or prognosing liver cancer in an individual, comprising the steps of:

a) determining the level of one or more RNA transcripts expressed in blood obtained from said individual, wherein said one or more RNA transcripts corresponds to said one or more biomarkers of Table 1 and

b) comparing the level of each of said one or more RNA transcripts in said blood according to step a) with the level of each of said one or more RNA transcripts in blood from one or more individuals having liver cancer,

c) comparing the level of each of said one or more RNA transcripts in said blood according to step a) with the level of each of said one or more RNA transcripts in blood from one or more individuals not having liver cancer,

d) determining whether the level of said one or more RNA transcripts of step a) classify with the levels of said transcripts in step b) as compared with levels of said transcripts in step c),

wherein said determination is indicative of said individual of step a) having liver cancer.

20. A method of diagnosing or prognosing liver cancer in an individual, comprising the steps of:

a) determining the level of one or more RNA transcripts expressed in blood obtained from said individual, wherein said one or more RNA transcripts corresponds to said one or more biomarkers of Table 1 and

b) comparing the level of each of said one or more RNA transcripts in said blood according to step a) with the level of each of said one or more RNA transcripts in blood from one or more individuals having liver cancer,

c) comparing the level of each of said one or more RNA transcripts in said blood according to step a) with the level of each of said one or more RNA transcripts in blood from one or more individuals not having liver cancer,

d) determining whether the level of said one or more RNA transcripts of step a) classify with the levels of said transcripts in step c) as compared with levels of said transcripts in step b),

wherein said determination is indicative of said individual of step a) not having liver cancer.

21. A method of diagnosing or prognosing liver cancer in an individual, comprising the steps of:

a) determining the level of one or more RNA transcripts expressed in blood obtained from said individual, wherein said one or more RNA transcripts corresponds to said one or more biomarkers of Table 1 and

b) using the results from step (a) in combination with a classifier so as to determine a diagnosis with respect to liver cancer.

36. A kit for diagnosing or prognosing liver cancer comprising:

a) two biomarker specific priming means designed to produce double stranded DNA complementary to a biomarker selected from Table 1;

wherein said first priming means contains a sequence which can selectively hybridize to RNA, cDNA or an EST complementary to said biomarker to create an extension product and said second priming means capable of selectively hybridizing to said extension product;

b) an enzyme with reverse transcriptase activity,

c) an enzyme with thermostable DNA polymerase activity, and

d) a labeling means;

wherein said primers are used to detect the quantitative expression levels of said biomarker in a test subject.

37. A method of diagnosing or prognosing liver cancer in an individual, comprising the steps of:

a) determining the level of one or more proteins expressed in blood obtained from said individual, wherein said one or more proteins is encoded by one or more biomarkers listed in Table 1, and

b) comparing the level of each of said one or more proteins in said blood according to step a) with the level of each of said one or more proteins in blood from one or more individuals not having liver cancer,

wherein detecting a difference in the levels of each of said one or more proteins in the comparison of step b) is indicative of liver cancer in the individual of step a).

41. The method of any one of claims 37-40, wherein the step of determining the level of each of said one or more proteins comprises the use of one or more antibodies, wherein each of said one or more antibodies is specific for a protein product of a biomarker listed in Table 1.

42. The method of claim 41, wherein said one or more antibodies is selected from the group consisting of a monoclonal antibody, fv. scfv, dab, fd, fab, and fab′

2.

38. A method of diagnosing or prognosing liver cancer in an individual, comprising the steps of:

a) determining the level of one or more proteins expressed in blood obtained from said individual, wherein said one or more proteins is encoded by said one or more biomarkers listed in Table 1, and

b) comparing the level of each of said one or more proteins in said blood according to step a) with the level of each of said one or more proteins in blood from one or more individuals having liver cancer,

wherein detecting the same levels of each of said one or more proteins in the comparison of step b) is indicative of liver cancer in the individual of step a).

39. A method of diagnosing or prognosing liver cancer in an individual, comprising the steps of:

a) determining the level of one or more proteins expressed in blood obtained from said individual, wherein said one or more proteins is encoded by said one or more biomarkers of Table 1, and

b) comparing the level of each of said one or more proteins in said blood according to step a) with the level of each of said one or more proteins in blood from one or more individuals having liver cancer,

c) comparing the level of each of said one or more proteins in said blood according to step a) with the level of each of said one or more proteins in blood from one or more individuals not having liver cancer,

d) determining whether the level of said one or moreproteins of step a) classify with the levels of said proteinss in step b) as compared with levels of said proteins in step c),

wherein said determination is indicative of said individual of step a) having liver cancer.

40. A method of diagnosing or prognosing liver cancer in an individual, comprising the steps of:

a) determining the level of one or more protein products expressed in blood obtained from said individual, wherein said one or more protein products corresponds to said one or more biomarkers of Table 1 and

b) using the results from step (a) in combination with a classifier so as to determine a diagnosis with respect to liver cancer.

43. A method of developing a classifier useful for diagnosing liver cancer, said method comprising:

(a) measuring the level of expression of the products of the biomarkers identified in Table 1 in a training population wherein said training population is comprised of two subgroups, a first subgroup diagnosed as having liver cancer and said second subgroup diagnosed as not having lvier cancer.

(b) apply one or more mathematical models to the levels of expression of step (a) to develop one or more classifiers which differentiate between said first subgroup and said second subgroup.

44. The method of claim 43 further comprising the step of evaluating one or more of said classifiers of step (b) for the classifier'"'"'s ability to properly characterize each individual of the training population.

45. The method of claim 43 further comprising the step of evaluating one or more of said classifiers of step (b) for the classifier'"'"'s ability to properly characterize one or more individuals of a population which is not the training population.